Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Synthomer Plc LSE:SYNT London Ordinary Share GB0009887422 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  1.80 0.37% 490.60 307,516 16:35:15
Bid Price Offer Price High Price Low Price Open Price
489.80 490.40 492.40 486.80 489.20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 1,644.20 20.30 0.70 700.9 2,084
Last Trade Time Trade Type Trade Size Trade Price Currency
17:29:50 O 10,495 490.60 GBX

Synthomer (SYNT) Latest News

More Synthomer News
Synthomer Investors    Synthomer Takeover Rumours

Synthomer (SYNT) Discussions and Chat

Synthomer Forums and Chat

Date Time Title Posts
14/4/202118:03Synthomer447
07/8/201819:23Synthomer (SYNT) One to Watch on Monday 1

Add a New Thread

Synthomer (SYNT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-04-16 16:30:00490.6010,49551,488.47O
2021-04-16 16:28:36491.044,87523,938.35O
2021-04-16 16:10:31490.631,2616,186.78O
2021-04-16 16:04:35489.3882401.29O
2021-04-16 16:03:54488.993641,779.92O
View all Synthomer trades in real-time

Synthomer (SYNT) Top Chat Posts

DateSubject
17/4/2021
09:20
Synthomer Daily Update: Synthomer Plc is listed in the Chemicals sector of the London Stock Exchange with ticker SYNT. The last closing price for Synthomer was 488.80p.
Synthomer Plc has a 4 week average price of 441.60p and a 12 week average price of 414p.
The 1 year high share price is 510p while the 1 year low share price is currently 238.40p.
There are currently 424,850,961 shares in issue and the average daily traded volume is 382,616 shares. The market capitalisation of Synthomer Plc is £2,084,318,814.67.
14/4/2021
10:02
philanderer: Morning JD UBS RAISES SYNTHOMER PRICE TARGET TO 495 (450) PENCE - 'NEUTRAL'
09/3/2021
12:23
philanderer: JEFFERIES RAISES SYNTHOMER PRICE TARGET TO 565 (545) PENCE - 'BUY'
23/2/2021
20:52
johnsoho: Two late purchases reported at 16.45, each of 303,000 shares at an share price price of 503.5. I wonder what actually is going on but suspect a bid for Synthomer maybe in the offing....time will tell
22/2/2021
14:11
philanderer: SYNT well in demand today :-O Results due on 4th march
11/2/2021
16:29
sphere25: Here we are, key price test coming up with the price currently at 463p. Don't do what IBST is doing. I can't take much more of that teasing :-D All imo DYOR
10/2/2021
15:04
sphere25: Further to previous posts here, we can all see how these dips are getting gobbled up. SYNT remains a buy the dip and it is reminiscent of wider markets really, particularly the US where it almost now feels a given that every little dip will get bought. Sellers came in here just above that 460p mark. They knocked the bid from around 463p downward to halt the breakout the last time I was observing so those will be the key levels to watch. All imo DYOR
01/2/2021
15:35
philanderer: No problem JD. All of a sudden SYNT is now the largest holding in my portfolio :-)
28/1/2021
13:57
philanderer: UBS RAISES SYNTHOMER PRICE TARGET TO 450 (325) PENCE - 'NEUTRAL'
20/1/2021
14:09
philanderer: Better today ;-) CREDIT SUISSE RAISES SYNTHOMER PRICE TARGET TO 515 (490) PENCE - 'OUTPERFORM' JEFFERIES RAISES SYNTHOMER PRICE TARGET TO 545 (440) PENCE - 'BUY'
15/9/2019
09:21
robow: GREAT IDEAS 10 | SHARES | 12 September 2019 Chemicals firm Synthomer (SYNT) looks very tempting at the current price following a big sell-off over the past year. The firm’s share price dropped from around 530p a year ago to 280p last month and saw the stock trade on nearly its lowest rating in a decade, while its level of debt compared to how much it’s earning is expected to double. But with the business on the cusp of global expansion as it aims to keep up with soaring demand for its products, investors with a long-term view may want to take advantage of the firm’s cheap valuation. The chemicals sector has historically been a good place to invest with significant share price gains over the past decade and occasionally generous dividends. But chemicals companies have been caught up by concerns over a global economic slowdown in the past year, and some in the market think this may feed into weaker demand for chemicals products. Synthomer has tried to expand significantly to keep up with demand for its speciality products, sought after due to many factors such as urbanisation, ageing demographics and stricter legislation. The firm supplies aqueous polymers to companies, which The company should benefit from capacity expansion and a deal to boost its position in the US and Europe The outlook is looking brighter for Synthomer Synthomer is also forecast by analysts at Canaccord and Numis to have a much stronger second half of this year as market conditions are set to improve. That combined with its completed upgrades to facilities in Germany and Malaysia means the firm will have greater capacity to meet demand for its products. Its net debt-to-earnings ratio is expected to increase next year to between 2.2 and 3-times as the Omnova deal is completed. But Synthomer has a clear plan to get this down below 2-times by the end of 2021. Its management team has a disciplined approach to M&A, with a ‘conservative capital’ policy meaning it’s unlikely to ever be reckless in the pursuit of growth. help create new products and boost the performance of existing ones, such as footwear insoles, condoms, packaging tapes, carpets and waterproofing products. While strong on the consumer side, investors had questioned Synthomer’s growth prospects given its lack of real penetration into the industrial market. But the proposed deal to acquire Omnova Solutions, an American speciality chemicals business operating in sectors like construction and oil and gas, could make the market reappraise Synthomer. As well as the US, Omnova has manufacturing and technical facilities in Europe, Thailand and China. Analysts at UBS believe the acquisition will help Synthomer sell more products in the US, and help it expand its facilities in Europe. SYNT is also forecast by analysts at Canaccord and Numis to have a much stronger second half of this year as market conditions are set to improve. That combined with its completed upgrades to facilities in Germany and Malaysia means the firm will have greater capacity to meet demand for its products. Its net debt-to-earnings ratio is expected to increase next year to between 2.2 and 3-times as the Omnova deal is completed. But Synthomer has a clear plan to get this down below 2-times by the end of 2021. Its management team has a disciplined approach to M&A, with a ‘conservative capital’ policy meaning it’s unlikely to ever be reckless in the pursuit of growth. help create new products
Synthomer share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
SYNT
Synthomer
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210417 15:00:48